Introduction
Failure investigations are one of the most consistently cited areas in FDA pharmaceutical GMP inspections. Failure to comply with 21 CFR 211.192, the core regulation governing pharmaceutical batch investigations, is regularly among the top reasons for FDA 483 observations. Yet the regulation itself is concise: any unexplained discrepancy or failure of a batch or its components to meet specifications shall be thoroughly investigated, whether or not the batch has already been distributed, and the investigation shall extend to other batches of the same drug product and other drug products associated with the specific failure.
The challenge is not in knowing the rule but in applying it correctly when the pressure to release a batch is high, when the root cause is ambiguous, or when the convenient answer is close at hand. This practice test is designed for quality control analysts, quality assurance managers, production supervisors, and regulatory affairs professionals preparing for GMP certification examinations or FDA inspection readiness.
Questions are drawn from the principles in FDA’s guidance for industry on investigating out-of-specification test results, the requirements of 21 CFR Parts 210 and 211, and the investigation failure patterns most frequently cited in Warning Letters and 483 observations.
Fundamentals
Question 1 (Beginner)
Under 21 CFR 211.192, when must a pharmaceutical manufacturer investigate a discrepancy or specification failure?
A) Only before the batch is distributed B) Only if the batch has already been recalled C) Whether or not the batch has already been distributed D) Only when the failure is confirmed on a second test
Correct answer: C
Why C is correct: The eCFR text of 21 CFR 211.192 states explicitly that the investigation must occur “whether or not the batch has already been distributed.” Distribution does not relieve the obligation to investigate, document conclusions, and take appropriate follow-up action.
Why the others are incorrect: – A: Limiting investigation to the pre-distribution window misses situations where defects or failures are detected after release, which are among the highest-risk scenarios given potential patient exposure. – B: A recall is a consequence that may follow an investigation, not a prerequisite for it. Many investigations are required in situations where no recall ultimately occurs. – D: As established consistently in FDA guidance, a passing second test result alone cannot invalidate an original out-of-specification (OOS) result without a formal investigation.
Knowledge expansion: The reach of 21 CFR 211.192 extends beyond the immediate batch. The investigation must also extend to other batches of the same drug product and to other drug products that may have been associated with the same failure or discrepancy. A narrowly scoped investigation that examines only the failed batch is not compliant with the full text of this regulation.
Question 2 (Beginner)
Which phase of an OOS investigation specifically focuses on whether the OOS result was caused by a laboratory error?
A) Phase 2 investigation B) Phase 1 laboratory investigation C) CAPA implementation D) Batch disposition review
Correct answer: B
Why B is correct: FDA’s guidance on investigating OOS test results establishes a two-phase framework. Phase 1 is the laboratory investigation, conducted by quality control/laboratory personnel, which examines whether an assignable laboratory cause (such as calculation error, sample preparation error, equipment malfunction, or analyst error) accounts for the OOS result. If a laboratory cause is identified and documented, the result may potentially be invalidated after supervisor review.
Why the others are incorrect: – A: Phase 2 is the broader production or process investigation conducted when Phase 1 has not identified a laboratory cause. It examines the manufacturing process, raw materials, equipment, and environment. – C: CAPA follows the investigation and addresses the root cause identified; it is not an investigative phase itself. – D: Batch disposition is a decision made based on the investigation’s conclusions, not an investigative phase.
Knowledge expansion: Phase 1 must be completed with rigour before Phase 2 is initiated. A common error is treating Phase 1 and Phase 2 as concurrent rather than sequential activities. If laboratory error is identified in Phase 1 and properly documented with supervisory approval, a retest may be conducted on the same sample. If Phase 1 finds no assignable laboratory cause, the OOS result stands and Phase 2 begins.
Question 3 (Beginner)
True or False: A passing retest result can be used to invalidate an original OOS result without a formal Phase 1 investigation.
Correct answer: False
Why False is correct: FDA’s OOS guidance is explicit: “Passing retest results alone cannot serve as the basis for invalidating OOS results.” The original OOS result requires investigation. Only if a laboratory error is identified and documented through that investigation can the result be invalidated. Testing into compliance without investigation is a data integrity violation and is among the most serious findings FDA makes during pharmaceutical inspections.
Knowledge expansion: “Testing into compliance” refers to the practice of retesting a sample until a passing result is obtained, and then using that passing result to release the batch without investigating the original OOS. This practice is not merely a procedural violation: it can result in releasing batches that genuinely fail specifications, potentially harming patients. FDA has pursued criminal enforcement in cases where this practice was systematic.
Compliance Requirements
Question 4 (Intermediate)
A quality control analyst obtains an OOS assay result for a finished pharmaceutical batch. The analyst’s supervisor reviews the calculation and confirms it is correct. No instrument malfunction is observed and the analyst is fully trained. What should happen next?
A) The batch should be rejected and destroyed B) A Phase 2 production investigation should be opened, examining manufacturing process, raw materials, and environment C) The analyst should prepare a fresh sample and retest D) The batch can be released based on the remaining in-specification results from the same test run
Correct answer: B
Why B is correct: If Phase 1 (laboratory investigation) fails to identify an assignable laboratory cause for the OOS result, the investigation proceeds to Phase 2: a broader examination of the manufacturing process, raw materials, equipment, environment, and any other factor that could have affected the batch. The OOS result remains standing and the batch remains on hold until the investigation is complete.
Why the others are incorrect: – A: Rejection is a disposition decision that may follow the investigation depending on its conclusions, but is not the automatic next step at this stage. – C: Without an identified laboratory cause documented in Phase 1, resampling and retesting is not the appropriate next step. Conducting additional tests without Phase 1 resolution risks “testing into compliance.” – D: Averaging an OOS result with passing results to generate an acceptable mean is explicitly prohibited by FDA as a basis for batch release.
Question 5 (Intermediate)
Under 21 CFR 211.192, the investigation of a batch failure must extend to what?
A) Only the specific batch that failed B) Other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy C) Only batches manufactured in the same month D) All batches manufactured on the same equipment, regardless of product type
Correct answer: B
Why B is correct: The eCFR text of 21 CFR 211.192 is clear: the investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. This reflects the principle that a root cause affecting one batch may affect others manufactured under the same conditions.
Why the others are incorrect: – A: A single-batch scope is explicitly insufficient under the regulation’s text. This is one of the most frequently cited investigation failures in FDA 483 observations. – C: The time frame is not the defining criterion for scope extension. The criterion is association with the failure or discrepancy, which could span any time period. – D: Extending to all batches on the same equipment regardless of product type would be unnecessarily broad in many cases. The investigation scope should be driven by the nature of the root cause, not by a blanket rule.
Knowledge expansion: Determining the appropriate scope of the investigation is a judgement that should be documented explicitly. If the investigation concludes that only one batch is affected, that conclusion should be supported by documented reasoning explaining why other batches are not at risk. An undocumented scope limitation is as problematic as an unjustified narrow scope.
Question 6 (Intermediate)
What must be included in the documentation of a pharmaceutical batch failure investigation?
A) Only the test results and the final batch disposition decision B) A clear statement of the reason for investigation, the results of a review to determine if the problem has occurred previously, and a description of corrective actions taken C) Only the analyst’s signature and the date the batch was released D) The names of all personnel in the facility at the time of the failure
Correct answer: B
Why B is correct: FDA’s OOS guidance specifies that investigation documentation must include: a clear statement of the reason for the investigation, the results of a review to determine if the problem has occurred previously, and a description of corrective actions taken. These requirements reflect the need to make the investigation auditable, to connect it to prior history, and to ensure CAPA is documented.
Why the others are incorrect: – A: Test results and disposition are necessary but not sufficient. The investigation record must explain the reasoning, assess prior occurrence, and document follow-up. – C: Analyst signature and batch disposition are elements of the batch record, not the full investigation documentation requirement. – D: Personnel lists are not an investigation documentation requirement under 21 CFR 211.192.
Investigation Methodology
Question 7 (Intermediate)
What is the most significant problem with concluding that a pharmaceutical batch failure was caused by “human error” without further investigation?
A) Human error is not an acceptable root cause under FDA regulations B) Human error is a symptom or proximate cause, not a root cause; the underlying systemic failure (in training, procedure, process design, or oversight) remains unaddressed C) CAPA cannot be written for human error findings D) Human error findings must be reported to FDA within 15 business days
Correct answer: B
Why B is correct: “Human error” describes what happened but not why the conditions existed that allowed the error to occur. A root cause analysis that stops at “human error” cannot drive an effective corrective action because the systemic conditions that permitted the error, inadequate training, unclear procedures, missing environmental controls, or insufficient oversight, remain in place. FDA consistently challenges “human error” as a final root cause.
Why the others are incorrect: – A: Human error is not prohibited as part of a root cause description, but it must be accompanied by analysis of why the error occurred at a systemic level. – C: CAPA can and should be written for human error findings, but the CAPA must address the system conditions that enabled the error, not just the individual’s behaviour. – D: No specific 15-day reporting timeline applies to internal investigation conclusions under pharmaceutical GMP regulations (15 business days applies in a different context under MoCRA for cosmetics adverse events).
Question 8 (Advanced)
During an OOS investigation, a Phase 2 examination identifies that a raw material lot used in the failed batch was also used in three other batches of the same product. Those three batches were released three months ago. What is the appropriate response?
A) No action is needed since the other batches have already been released and presumably have not caused any complaints B) The three released batches should be investigated to determine whether they may also be affected, and the investigation findings should inform disposition decisions about those batches C) The supplier should be asked to provide a certificate of analysis for the raw material lot and the matter can be closed D) The investigation should be closed and a new one opened specifically for the raw material lot
Correct answer: B
Why B is correct: 21 CFR 211.192 requires the investigation to extend to other batches associated with the specific failure or discrepancy. If the root cause implicates a raw material lot used in multiple batches, the investigation must assess whether those batches are affected, regardless of whether they have already been distributed. The outcome of that assessment drives disposition decisions, which may include field alerts, recalls, or monitoring depending on the risk.
Why the others are incorrect: – A: The absence of complaints does not mean the batches meet specifications. Specification failures can exist without generating reportable adverse events, particularly for OOS results on parameters that don’t produce immediate clinical symptoms. – C: A certificate of analysis from the supplier documents what the supplier tested, not what the manufacturer’s own testing showed. The investigation must account for the manufacturer’s own quality data, not just supplier documentation. – D: The investigation should remain unified. Artificially segmenting investigations to limit their scope is a data integrity concern if done to avoid extending findings.
Scenario-Based Learning
Question 9 (Advanced - Scenario)
A pharmaceutical manufacturing site has received an FDA 483 observation for “failure to adequately investigate OOS results.” The site’s quality director reviews the past year’s OOS records and finds that in 14 out of 20 cases, the investigation was closed with the conclusion “laboratory error, analyst retrained.” No root cause analysis beyond this conclusion was conducted. What is the systemic problem, and what should the CAPA address?
A) The lab analysts need more training B) The investigation system has a structural gap: it accepts “laboratory error” as a final root cause without requiring analysis of why the errors occurred, what systemic conditions enabled them, or whether the retraining was effective C) The site should outsource its testing to a contract laboratory to reduce OOS rates D) The OOS rate is too high and the site should adjust its specifications
Correct answer: B
Why B is correct: A pattern of 70 percent of OOS investigations concluding with “laboratory error, analyst retrained” is a systemic quality system failure, not a collection of unrelated analyst mistakes. The CAPA must address the investigation system itself: the procedure must require analysis of why errors occur (not just that they occurred), the conditions that enable them, and documented verification that retraining or other actions were effective. An investigation procedure that accepts “analyst retrained” as a complete response has not produced a CAPA.
Why the others are incorrect: – A: More training for analysts does not address the systemic failure in how investigations are conducted and closed. It also assumes the root cause is analyst competency, which the pattern suggests is incorrect. – C: Outsourcing testing does not resolve the investigation system failure and may create new compliance complexity. – D: Adjusting specifications to eliminate OOS results is not an appropriate response to investigation failures. Specifications exist to protect product quality; changing them to make failures disappear is a data integrity violation.
Knowledge expansion: A pattern of OOS closures that all cite the same root cause should trigger a meta-level review: is this pattern the result of a genuine reoccurring problem with the same root cause, or is it the result of a template-driven investigation system that generates similar conclusions regardless of the actual event? FDA inspectors are trained to identify both patterns.
Question 10 (Advanced - Scenario)
An FDA investigator is reviewing a pharmaceutical site’s batch records and notes that a batch with an initial OOS microbiological result was subsequently released based on a “passing” retest. The investigation record states that the original analyst was new and may have made a sample preparation error, and that the retest was conducted by a senior analyst who obtained a passing result. No specific laboratory error was identified. Should the original OOS result have been invalidated on this basis?
A) Yes, because a senior analyst’s passing result overrides a junior analyst’s OOS result B) No, because a suspected but unconfirmed analyst error is not sufficient grounds for invalidating an OOS result; a specific, documented laboratory error must be identified for invalidation C) Yes, because the subsequent retest demonstrates the product meets specifications D) It depends on whether the batch was used in clinical trials
Correct answer: B
Why B is correct: FDA’s OOS guidance is specific: an OOS result can only be invalidated if a specific laboratory cause is identified, not merely suspected. The fact that the analyst was new creates a hypothesis, but a hypothesis without identified specific error is not an invalidation basis. The original OOS result should have stood, and Phase 2 should have been initiated. Invalidating an OOS result on the basis of “the analyst may have made an error” is the textbook definition of testing into compliance.
Why the others are incorrect: – A: Analyst seniority is not an investigative criterion. The original test result stands unless a specific error in that test is identified and documented. – C: A passing retest does not demonstrate the original result was wrong; it demonstrates that the retest produced a different result. Both results are part of the data set until one is properly invalidated through investigation. – D: The invalidation standard is not affected by whether the batch was used in clinical trials; the same investigation requirements apply.
Advanced Scenarios
Question 11 (Advanced)
A pharmaceutical quality unit is reviewing its CAPA effectiveness metrics. It finds that 35 percent of CAPAs generated from failure investigations were reopened within 12 months due to recurrence of the same problem. What does this pattern most likely indicate?
A) The site has an unusually high frequency of random manufacturing variability B) The root cause analysis step is producing superficial or incorrect root cause identifications, leading to CAPAs that do not address the actual failure mechanism C) The CAPA closure process is too strict D) The verification of effectiveness step is working correctly by catching recurrences
Correct answer: B
Why B is correct: A 35 percent recurrence rate within 12 months is a strong signal that root causes are not being correctly identified. When the root cause is wrong, the corrective action addresses the wrong thing, the failure mode remains in place, and recurrence follows. This is a quality system signal that should trigger a meta-CAPA addressing the investigation and root cause analysis process itself.
Why the others are incorrect: – A: While manufacturing variability exists, a systematic recurrence pattern across 35 percent of CAPAs cannot be attributed to random variability. It indicates a process gap. – C: CAPA closure criteria should ensure that corrective actions are implemented and verified. Overly strict closure is not what a 35 percent recurrence rate indicates. – D: VoE identifies recurrences, but it is not functioning correctly in this scenario because recurrences are happening at all. VoE should confirm that actions worked; a 35 percent recurrence rate means actions often did not work.
Question 12 (Beginner)
Which of the following best describes the role of the Quality Control Unit (QCU) under 21 CFR 211.192 in pharmaceutical batch investigations?
A) The QCU is optional for investigation oversight if the production department has sufficient quality resources B) The QCU must review and approve all production and control records before batch release, and must oversee investigation and CAPA activities C) The QCU only needs to be involved if the batch is being rejected D) The QCU’s role is limited to reviewing analytical test results
Correct answer: B
Why B is correct: Under 21 CFR 211.192 and 21 CFR 211.22, the QCU has the authority and responsibility to review production and control records before batch release and to approve or reject batches. The QCU is also responsible for investigating OOS results and failures, reviewing CAPA adequacy, and ensuring that investigation conclusions are documented with appropriate oversight. Deficient QCU oversight is consistently cited by FDA as a companion finding to inadequate investigations.
Why the others are incorrect: – A: The QCU is not optional. Its independence from production operations is a structural GMP requirement. – C: The QCU’s involvement is not triggered by rejection; it is required throughout the investigation and disposition process regardless of outcome. – D: The QCU’s responsibilities extend well beyond analytical test result review to encompass all aspects of batch release and quality system oversight.
Topic Categorisation
Compliance Requirements
| Requirement | Regulatory reference |
|---|---|
| Investigate all unexplained discrepancies and specification failures | 21 CFR 211.192 |
| Extend investigation to other potentially affected batches | 21 CFR 211.192 |
| Document conclusions and follow-up | 21 CFR 211.192 |
| Conduct Phase 1 laboratory investigation before Phase 2 | FDA OOS guidance |
| Do not use passing retests to invalidate OOS results without laboratory error identification | FDA OOS guidance |
| QCU review and approval of production and control records | 21 CFR 211.22, 211.192 |
| CAPA must be implemented for identified root causes | 21 CFR 211.192, ICH Q10 |
| CAPA effectiveness must be verified | ICH Q10, FDA CAPA expectations |
Scenario-Based Learning: Two Additional Questions
Question 13 (Intermediate - Scenario)
A pharmaceutical site receives an FDA 483 observation stating: “Failure to extend the investigation of a failing batch to other batches of the same drug product.” The site’s response argues that the other batches were manufactured on different days and by different operators, so they could not be affected. Is this a sufficient justification?
A) Yes, different operators and days means the other batches are independent of the failure B) No, the investigation must assess whether the root cause could have affected other batches regardless of operator or production date, unless the root cause has been specifically identified and shown not to apply to those batches C) Yes, if the other batches have passing release test results, they are demonstrated to be unaffected D) It depends on whether the other batches have been distributed
Correct answer: B
Why B is correct: The argument that batches from different operators and different days are automatically unrelated is insufficient without a documented root cause that specifically explains why those variables are the determining factor. If the root cause is, for example, a raw material supplier issue, different operators and dates are irrelevant. The extension of scope must be driven by the root cause, not by the assumption of independence.
Why the others are incorrect: – A: Operator and date variation do not automatically exclude shared root causes. Many failure modes (contamination, equipment calibration drift, raw material issues) affect multiple production runs regardless of operator. – C: Passing release tests demonstrate that the tested parameters met specification at the time of testing, but cannot rule out failure modes that may not have been captured in the release testing panel. – D: Distribution status affects urgency and potential consequences, but not the requirement to assess other batches.
Question 14 (Advanced)
True or False: An investigation under 21 CFR 211.192 can be closed as “inconclusive” if no specific root cause is identified, and the batch can be released based on passing retest results in this case.
Correct answer: False, with important nuance
Why this requires nuance: An investigation can be designated as inconclusive if Phase 1 finds no laboratory cause and Phase 2 fails to identify a manufacturing root cause. However, in that case the OOS result must be given full consideration in the batch disposition decision. An inconclusive investigation does not automatically permit batch release. The Quality Unit may decide to release the batch if a comprehensive investigation failed to confirm the OOS and if the overall data supports that conclusion, but this decision requires documented justification and is not the same as closing an investigation because a convenient retest produced a passing result.
Knowledge expansion: FDA’s OOS guidance provides a specific example: an initial OOS assay result of 89.5 percent (against a lower limit of 90.0 percent), followed by six retests all in the 98.8-99.1 percent range and no laboratory error identified, might support release with documented justification if a comprehensive investigation was conducted. The key is that the comprehensive investigation must have been conducted first, not bypassed in favour of the retests.
Supporting Resources
For further study on the topics covered in this practice test:
- A complete guide to failure investigations for pharmaceutical manufacturers, covering the step-by-step process, Phase 1 and Phase 2 investigation frameworks, CAPA requirements, and common 483 findings, is available in the Guides section.
- An Insights analysis of CAPA failure patterns in FDA pharmaceutical and device inspections in 2024 is available in the Insights section.
- FDA’s published guidance document “Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production” is the primary reference for OOS investigation requirements and is publicly available on FDA.gov.
Sources
- eCFR, “21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals”
- FDA, “Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production”
- DSDP Analytics, “21 CFR Part 211.192”
- The FDA Group, “21 CFR 211.192: An Introduction and Compliance Guide”
- Tricentis, “A Comprehensive Guide to FDA 21 CFR Part 211”
- Scholars Research Library, “Investigating OOS Results and Development of CAPA Program for Pharmaceutical Industries”
- Pharmanow, “Regulatory Compliance in Pharma Manufacturing: Key Challenges and CAPA”